Assignee
GEOVAX INC
US·14 granted patents·7 pending applications·16 citations·filing 2012–2023
Top patents by PatentIndex Score
21 records- 0191US11311612B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2018·Granted Apr 26, 2022·6 cites·17 claims
- 0290US11857611B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2022·Granted Jan 2, 2024·2 cites·22 claims
- 0388US11098086B2Multivalent HIV vaccine boost compositions and methods of useGEOVAX INC·Filed 2017·Granted Aug 24, 2021·3 cites·22 claims
- 0485US11278607B2Compositions and methods for generating an immune response to a tumor associated antigenGEOVAX INC·Filed 2017·Granted Mar 22, 2022·2 cites·19 claims
- 0584US11052148B2Compositions and methods for generating an immune response to hepatitis B virusGEOVAX INC·Filed 2017·Granted Jul 6, 2021·2 cites·11 claims
- 0683US12370249B2Replication-deficient modified vaccinia ankara (MVA) expressing marburg virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2023·Granted Jul 29, 2025·0 cites·22 claims
- 0782US12329808B2Compositions and methods for generating an immune response to treat or prevent malariaGEOVAX INC·Filed 2023·Granted Jun 17, 2025·0 cites·17 claims
- 0881US11413341B2Vaccinia viral vectors encoding chimeric virus like particlesGEOVAX INC·Filed 2020·Granted Aug 16, 2022·1 cites·14 claims
- 0973US12247214B2Vaccinia viral vectors encoding chimeric virus like particlesGEOVAX INC·Filed 2022·Granted Mar 11, 2025·0 cites·21 claims
- 1073US11896657B2Replication-deficient modified vaccinia Ankara (MVA) expressing Marburg virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2022·Granted Feb 13, 2024·0 cites·11 claims
- 1170US11897919B2Multivalent HIV vaccine boost compositions and methods of useGEOVAX INC·Filed 2021·Granted Feb 13, 2024·0 cites·14 claims
- 1270US2023256088A1Immuno-oncology compositions and methods for use thereofGEOVAX INC·Filed 2022·Application pending·0 cites
- 1365US12577589B2Vaccines and uses thereof to induce an immune response to SARS-CoV2GEOVAX INC·Filed 2022·Granted Mar 17, 2026·0 cites·28 claims
- 1464US11638750B2Methods for generating a Zikv immune response utilizing a recombinant modified vaccina Ankara vector encoding the NS1 proteinGEOVAX INC·Filed 2020·Granted May 2, 2023·0 cites·22 claims
- 1560US11701418B2Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)GEOVAX INC·Filed 2016·Granted Jul 18, 2023·0 cites·27 claims
- 1659US2021220469A1Immuno-Oncology Compositions and Methods for Use ThereofGEOVAX INC·Filed 2018·Application pending·0 cites
- 1758US2024344082A1Viral constructs for use in enhancing t-cell priming during vaccinationGEOVAX INC·Filed 2023·Application pending·0 cites
- 1857US2022160853A1Cancer vaccine compositions and methods for use thereofGEOVAX INC·Filed 2021·Application pending·0 cites
- 1951US2019030157A1Compositions and Methods for Generating an Immune Response to a FlavivirusGEOVAX INC·Filed 2017·Application pending·0 cites
- 2046US2020171141A1Compositions and Methods for Generating an Immune Response to LASVGEOVAX INC·Filed 2018·Application pending·0 cites
- 2145US2013280215A1Mva vectors expressing polypeptides and having high level production in certain cell linesGEOVAX INC·Filed 2012·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →